Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

Routine testing for a specific lipoprotein known as Lp(a) would be a cost-saving way to significantly reduce the risk of cardiovascular disease and save lives, according to an international research ...